This topic contains a solution. Click here to go to the answer

Author Question: A patient with Parkinson's disease has been achieving effective symptom control with levodopa ... (Read 33 times)

dalyningkenk

  • Hero Member
  • *****
  • Posts: 598
A patient with Parkinson's disease has been achieving effective symptom control with levodopa (Dopar) but complains that the symptoms begin to return before it is time for the next dose. The drug just wears off, he states.
 
  The nurse should anticipate that the prescriber will order the pa-tient to a. take the levodopa at shorter dosing intervals.
  b. start taking a drug that reduces levodopa's half-life.
  c. take levodopa at longer dosing intervals.
  d. increase the dose to increase receptor binding.

Question 2

An obese patient is admitted to the unit. The blood glucose level is 379, urinalysis reveals glycosuria, blood pressure is 178/99, and the patient complains of muscle aches and weakness.
 
  The patient also exhibits a moon face and buffalo hump. The nurse recognizes these signs and symptoms as ___________________ ___ and anticipates ___________________ __. a. Graves' disease; treatment directed at the cause
  b. Addison's disease; administration of fludrocortisone
  c. Cushing's syndrome; treatment directed at the cause
  d. diabetes; insulin replacement therapy



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
Marked as best answer by a Subject Expert

Dnite

  • Sr. Member
  • ****
  • Posts: 297
Answer to Question 1

A
Gradual loss (wearing off) develops near the end of the dosing interval and simply indicates that drug levels have declined to a subtherapeutic value. Wearing off can be minimized by shortening the dosing interval.
Giving a drug that prolongs levodopa's plasma half-life and giving a direct-acting dopamine agonist would be effective; giving a drug that reduces levodopa's half-life would not.
Levodopa should be taken at shorter dosing intervals, not longer ones.
Increasing the dose does not increase receptor binding. The availability of receptor binding makes a difference, and as does the drug's affinity for the receptor.

Answer to Question 2

C
Cushing's syndrome is manifested by obesity, hyperglycemia, glycosuria, hypertension, fluid and electrolyte disturbances, osteoporosis, muscle weakness, myopathy, hirsutism, a moon face, and a buffalo hump. Treatment is directed at the cause.
Graves' disease is not associated with the adrenal gland, but rather with the thyroid gland.
Addison's disease is manifested by weakness, emaciation, hypoglycemia, and increased pigmen-tation of the skin and mucous membranes.
Diabetes is manifested in many ways but not by a moon face or buffalo hump.




dalyningkenk

  • Member
  • Posts: 598
Reply 2 on: Jul 23, 2018
Thanks for the timely response, appreciate it


bdobbins

  • Member
  • Posts: 326
Reply 3 on: Yesterday
Excellent

 

Did you know?

Atropine was named after the Greek goddess Atropos, the oldest and ugliest of the three sisters known as the Fates, who controlled the destiny of men.

Did you know?

Despite claims by manufacturers, the supplement known as Ginkgo biloba was shown in a study of more than 3,000 participants to be ineffective in reducing development of dementia and Alzheimer’s disease in older people.

Did you know?

Critical care patients are twice as likely to receive the wrong medication. Of these errors, 20% are life-threatening, and 42% require additional life-sustaining treatments.

Did you know?

According to animal studies, the typical American diet is damaging to the liver and may result in allergies, low energy, digestive problems, and a lack of ability to detoxify harmful substances.

Did you know?

This year, an estimated 1.4 million Americans will have a new or recurrent heart attack.

For a complete list of videos, visit our video library